Clinilabs Inc

1. ITI, Inc. $2,632,208 51 payments
2. Biogen, Inc. $2,445,099 18 payments
3. Janssen Research & Development, LLC $1,249,466 45 payments
4. Pfizer Inc. $875,374 41 payments
5. Imbrium Therapeutics L.P. $98,668 12 payments
6. Sage Therapeutics, Inc. $21,454 4 payments
7. H. Lundbeck A S $12,664 2 payments
8. Novartis Pharmaceuticals Corporation $3,112 1 payment
9. Takeda Pharmaceuticals U.S.A., Inc. $434 1 payment

1. A 2-Part Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Vixotrigine (BIIB074) Following Multiple Oral Doses at Therapeutic and Supratherapeutic Dose Levels (Part 1), and a Randomized, Double-Blind, Placebo- and Positive-Controlled (Moxifloxacin), Parallel Study with a Nested Crossover to Assess the Effect of Multiple Oral Supratherapeutic Doses of Vixotrigine on Cardiac Repolarization (Part 2) in Healthy Subjects $1,833,889 2 payments
2. A Randomized, Double-Blind, Placebo-Controlled, Single Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Iti-333 in Normal Healthy Volunteers $1,604,180 30 payments
3. A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Escalating Doses of Iti-333 in Healthy Subjects $813,247 19 payments
4. A Phase 3 Multicenter Placebocontrolled Randomized Observerblinded Trial to Evaluate the Efficacy Safety Tolerability Immunogenicity and Lot Consistency of A 6Valent Ospabased Lyme Disease Vaccine in Healthy Participants 5 Years of Age $616,037 31 payments
5. An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression $583,218 25 payments
6. A Multi Center Randomized Double Blind Placebo Controlled Multiple Dose 2period Crossover Sleep Laboratory Study to Assess the Effect of Seltorexant Compared to Placebo on Respiration During Sleep in Adult Patients with Obstructive Sleep Apnea $527,276 11 payments
7. Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease $329,466 2 payments
8. A Phase 1 Randomized Doubleblind Sponsor Open Placebo Controlled Dose Escalating Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of Single Intravenous and Multiple Subcutaneous and Intravenous Doses of Pf07261271 in Healthy Participants $259,337 10 payments
9. Iti-333 Sad Study $214,781 2 payments
10. A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration $180,195 3 payments

1. Other $434 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.